Francis Spinale to Heart Failure
This is a "connection" page, showing publications Francis Spinale has written about Heart Failure.
Connection Strength
6.104
-
Ubiquitin ligase Wwp1 gene deletion attenuates diastolic dysfunction in pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol. 2021 11 01; 321(5):H976-H984.
Score: 0.414
-
The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. Am J Physiol Heart Circ Physiol. 2020 10 01; 319(4):H765-H774.
Score: 0.384
-
Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
Score: 0.378
-
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype. Nat Rev Cardiol. 2020 08; 17(8):523-531.
Score: 0.364
-
Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure. Stress. 2019 09; 22(5):530-547.
Score: 0.353
-
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA Cardiol. 2018 12 01; 3(12):1232-1243.
Score: 0.341
-
Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
Score: 0.340
-
Integrating the myocardial matrix into heart failure recognition and management. Circ Res. 2013 Aug 30; 113(6):725-38.
Score: 0.237
-
Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
Score: 0.226
-
Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol. 2013 Jan 01; 85(1):1-11.
Score: 0.221
-
Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012 Jan; 8(1):7-20.
Score: 0.211
-
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
Score: 0.204
-
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail. 2009 May; 2(3):262-71.
Score: 0.175
-
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006 Feb 15; 69(3):666-76.
Score: 0.140
-
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
Score: 0.133
-
Disruptions and detours in the myocardial matrix highway and heart failure. Curr Heart Fail Rep. 2005 Mar; 2(1):10-7.
Score: 0.131
-
Caspase inhibition attenuates contractile dysfunction following cardioplegic arrest and rewarming in the setting of left ventricular failure. J Cardiovasc Pharmacol. 2004 Dec; 44(6):645-50.
Score: 0.129
-
Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J. 2004 Apr; 25(8):631-3.
Score: 0.123
-
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
Score: 0.114
-
Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol. 2003 Jan-Feb; 10(1):77-86.
Score: 0.113
-
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
Score: 0.112
-
Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
Score: 0.112
-
Interpretable machine learning predicts cardiac resynchronization therapy responses from personalized biochemical and biomechanical features. BMC Med Inform Decis Mak. 2022 10 31; 22(1):282.
Score: 0.112
-
Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg. 2002 May; 194(5):603-9.
Score: 0.108
-
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1288-95.
Score: 0.107
-
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
Score: 0.107
-
Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H798-H805.
Score: 0.107
-
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
Score: 0.107
-
Speckle-Tracking Echocardiography Enables Model-Based Identification of Regional Stiffness Indices in the Left Ventricular Myocardium. Cardiovasc Eng Technol. 2020 04; 11(2):176-187.
Score: 0.092
-
Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):636-46.
Score: 0.070
-
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012 Jun 22; 111(1):131-50.
Score: 0.054
-
Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
Score: 0.049
-
Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine. Circulation. 2010 Jul 27; 122(4):322-4.
Score: 0.048
-
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
Score: 0.047
-
SmartDelay determined AV optimization: a comparison of AV delay methods used in cardiac resynchronization therapy (SMART-AV): rationale and design. Pacing Clin Electrophysiol. 2010 Jan; 33(1):54-63.
Score: 0.045
-
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail. 2008 Feb; 10(2):125-8.
Score: 0.040
-
Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
Score: 0.036
-
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
Score: 0.009
-
Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation. 2004 Oct 05; 110(14):e333-6.
Score: 0.008